OpenSourceTB:OSTB Series 1: Difference between revisions
Matthew Todd (talk | contribs) (→Strings: added strings from Project 1) |
Matthew Todd (talk | contribs) (→Preliminary Work on the Series Outside GSK: added scheme of second round) |
||
Line 26: | Line 26: | ||
===Project 2=== | ===Project 2=== | ||
Exploration of the heterocycle was performed by Javier González Osende at The University of Sydney. Preliminary biological evaluation was performed by Jamie Triccas at The University of Sydney, and full evaluation was performed by GSK Tres Cantos. The data obtained are summarised below. | |||
[[Image:Second Round GSK.png|thumb|center|700px| '''Compounds Synthesized in the Second Round, and their Potencies''']] | |||
==Current Activity== | ==Current Activity== |
Revision as of 08:48, 8 October 2014
Background to the Spiro Series
In XXXX GSK performed a phenotypic screen against M. bovis BCG as a surrogate of the virulent strain of Mycobacterium tuberculosis (H37Rv), ultimately discovering 177 small molecules displaying <10 micro molar inhibitory concentration against H37Rv which also possessed favorable good membrane permeability, alignment with the Rule of 5.
One such series, the Spiros, were viewed as one of seven particularly promising sets of compounds because of their XXX.
The two lead members of this series were
Preliminary Work on the Series Outside GSK
Two open research projects have been completed on analog synthesis and evaluation.
Project 1
Exploration of the N-substituent was performed by Katrina Badiola at The University of Sydney, with the following data being obtained by Jamie Triccas at the same university.
One compound (OSTBS4, TCMDC-142379, GSK2200150A) had been tested previously by GSK (CHEMBL2098175), and one has been made previously for a non-TB project.
A paper describing this project is in press in PLoS ONE.
Project 2
Exploration of the heterocycle was performed by Javier González Osende at The University of Sydney. Preliminary biological evaluation was performed by Jamie Triccas at The University of Sydney, and full evaluation was performed by GSK Tres Cantos. The data obtained are summarised below.
Current Activity
Other Sources of These, or Similar, Compounds
Commercial
Literature
Strings
(Makes molecules on this page machine-discoverable)
OSTBS1 [H]N(CC1)CCC21C3=C(SC=C3)CCO2 InChI=1S/C11H15NOS/c1-7-13-11(3-5-12-6-4-11)9-2-8-14-10(1)9/h2,8,12H,1,3-7H2 KARGZLCFESUWBW-UHFFFAOYSA-N
OSTBS2 C12=C(SC=C2)CCOC13CCN(CC4=CC=CC=C4)CC3 InChI=1S/C18H21NOS/c1-2-4-15(5-3-1)14-19-10-8-18(9-11-19)16-7-13-21-17(16)6-12-20-18/h1-5,7,13H,6,8-12,14H2 WRPOPKKINJVHKF-UHFFFAOYSA-N CHEMBL2064198
OSTBS3 O=C(OCCCl)N(CC1)CCC21C3=C(SC=C3)CCO2 InChI=1S/C14H18ClNO3S/c15-5-9-18-13(17)16-6-3-14(4-7-16)11-2-10-20-12(11)1-8-19-14/h2,10H,1,3-9H2 RXXGDCXYAFFODV-UHFFFAOYSA-N
OSTBS4 C12=C(SC=C2)CCOC13CCN(CC4=CC(OCCO5)=C5C=C4)CC3 InChI=1S/C20H23NO3S/c1-2-17-18(23-11-10-22-17)13-15(1)14-21-7-5-20(6-8-21)16-4-12-25-19(16)3-9-24-20/h1-2,4,12-13H,3,5-11,14H2 NCRPMBWORFWNGT-UHFFFAOYSA-N CHEMBL2098175 TCMDC-142379 GSK2200150A
OSTBS5 C12=C(SC=C2)CCOC13CCN(CC4=CC(OCO5)=C5C=C4)CC3 InChI=1S/C19H21NO3S/c1-2-16-17(22-13-21-16)11-14(1)12-20-7-5-19(6-8-20)15-4-10-24-18(15)3-9-23-19/h1-2,4,10-11H,3,5-9,12-13H2 ACOYQJHGMQYDJB-UHFFFAOYSA-N
OSTBS6 OC(C=C1)=C(OC)C=C1CN(CC2)CCC32C4=C(SC=C4)CCO3 InChI=1S/C19H23NO3S/c1-22-17-12-14(2-3-16(17)21)13-20-8-6-19(7-9-20)15-5-11-24-18(15)4-10-23-19/h2-3,5,11-12,21H,4,6-10,13H2,1H3 KBNYOKOGHUQGHP-UHFFFAOYSA-N
OSTBS7 ClC(C=C1)=CC=C1CN(CC2)CCC32C4=C(SC=C4)CCO3 InChI=1S/C18H20ClNOS/c19-15-3-1-14(2-4-15)13-20-9-7-18(8-10-20)16-6-12-22-17(16)5-11-21-18/h1-4,6,12H,5,7-11,13H2 IKDZLARXTXDYSV-UHFFFAOYSA-N
OSTBS8 (HCl salt of OSTBS9) CC1=CC(CN(CC2)CCC32C4=C(SC=C4)CCO3)=C(C)N1C5=CC=C(F)C=C5.Cl InChI=1S/C24H27FN2OS.ClH/c1-17-15-19(18(2)27(17)21-5-3-20(25)4-6-21)16-26-11-9-24(10-12-26)22-8-14-29-23(22)7-13-28-24;/h3-6,8,14-15H,7,9-13,16H2,1-2H3;1H MHQORCJLAHARKG-UHFFFAOYSA-N
OSTBS9 (free amine on OSTBS8) CC1=CC(CN(CC2)CCC32C4=C(SC=C4)CCO3)=C(C)N1C5=CC=C(F)C=C5 InChI=1S/C24H27FN2OS/c1-17-15-19(18(2)27(17)21-5-3-20(25)4-6-21)16-26-11-9-24(10-12-26)22-8-14-29-23(22)7-13-28-24/h3-6,8,14-15H,7,9-13,16H2,1-2H3 JOUHIYBEDRSIMN-UHFFFAOYSA-N
OSTBS10 C12=C(SC=C2)CCOC13CCN(C4CCCCC4)CC3 InChI=1S/C17H25NOS/c1-2-4-14(5-3-1)18-10-8-17(9-11-18)15-7-13-20-16(15)6-12-19-17/h7,13-14H,1-6,8-12H2 XLYPXGDSQIIAGC-UHFFFAOYSA-N
OSTBS11 O=C(C1=CC=CC=C1)N(CC2)CCC32C4=C(SC=C4)CCO3 InChI=1S/C18H19NO2S/c20-17(14-4-2-1-3-5-14)19-10-8-18(9-11-19)15-7-13-22-16(15)6-12-21-18/h1-5,7,13H,6,8-12H2 DJCDYAUIXOORLS-UHFFFAOYSA-N
OSTBS12 O=C(C1=CC=C(Br)C=C1)N(CC2)CCC32C4=C(SC=C4)CCO3 InChI=1S/C18H18BrNO2S/c19-14-3-1-13(2-4-14)17(21)20-9-7-18(8-10-20)15-6-12-23-16(15)5-11-22-18/h1-4,6,12H,5,7-11H2 NZVHUZGXLTUEBD-UHFFFAOYSA-N
OSTBS13 O=C(C1=C(Br)C=CC=C1)N(CC2)CCC32C4=C(SC=C4)CCO3 InChI=1S/C18H18BrNO2S/c19-15-4-2-1-3-13(15)17(21)20-9-7-18(8-10-20)14-6-12-23-16(14)5-11-22-18/h1-4,6,12H,5,7-11H2 LHLPZMBZHPYLMM-UHFFFAOYSA-N
OSM-S-210 GSK2200150A C12=C(SC=C2)CCOC13CCN(CC4=CC(OCCO5)=C5C=C4)CC3 InChI=1S/C20H23NO3S/c1-2-17-18(23-11-10-22-17)13-15(1)14-21-7-5-20(6-8-21)16-4-12-25-19(16)3-9-24-20/h1-2,4,12-13H,3,5-11,14H2
NCRPMBWORFWNGT-UHFFFAOYSA-N
OSM-S-194 GSK3376889A
C12=C(C(C=CC=C3)=C3N2)CCOC14CCN(CC5=CC=CC=C5)CC4 InChI=1S/C22H24N2O/c1-2-6-17(7-3-1)16-24-13-11-22(12-14-24)21-19(10-15-25-22)18-8-4-5-9-20(18)23-21/h1-9,23H,10-16H2 ZZRXZXUKZZBHSK-UHFFFAOYSA-N
OSM-S-195 GSK3376890A ClC1=CC=CC2=C1CCOC23CCN(CC4=CC=CC=C4)CC3 InChI=1S/C20H22ClNO/c21-19-8-4-7-18-17(19)9-14-23-20(18)10-12-22(13-11-20)15-16-5-2-1-3-6-16/h1-8H,9-15H2 MMFIRWPCCHXYHI-UHFFFAOYSA-N
OSM-S-196 GSK3376891A COC(C(OC)=C1)=CC2=C1C3(CCN(CC4=CC=CC=C4)CC3)OCC2 InChI=1S/C22H27NO3/c1-24-20-14-18-8-13-26-22(19(18)15-21(20)25-2)9-11-23(12-10-22)16-17-6-4-3-5-7-17/h3-7,14-15H,8-13,16H2,1-2H3 ADXUPDCQQACVPU-UHFFFAOYSA-N
OSM-S-197 GSK3376892A C12=C(C(C=CC=C3)=C3N2)CCOC14CCNCC4 InChI=1S/C15H18N2O/c1-2-4-13-11(3-1)12-5-10-18-15(14(12)17-13)6-8-16-9-7-15/h1-4,16-17H,5-10H2 ADIFMQFOYVKYJG-UHFFFAOYSA-N
OSM-S-198 GSK3376893A C12=C(C=CS2)CCOC13CCN(CC4=CC=CC=C4)CC3 InChI=1S/C18H21NOS/c1-2-4-15(5-3-1)14-19-10-8-18(9-11-19)17-16(6-12-20-18)7-13-21-17/h1-5,7,13H,6,8-12,14H2 ZZQIGFUYNABBCP-UHFFFAOYSA-N
OSM-S-199 GSK3376894A C12=C(C(C=CC=C3)=C3N2)CCOC14CCN(CC5=CC(OCCO6)=C6C=C5)CC4 InChI=1S/C24H26N2O3/c1-2-4-20-18(3-1)19-7-12-29-24(23(19)25-20)8-10-26(11-9-24)16-17-5-6-21-22(15-17)28-14-13-27-21/h1-6,15,25H,7-14,16H2 VOUYSWHZMJVQFH-UHFFFAOYSA-N
OSM-S-200 GSK3376895A C12=C(C(C=CC=C3)=C3S2)CCOC14CCN(CC5=CC=CC=C5)CC4 InChI=1S/C22H23NOS/c1-2-6-17(7-3-1)16-23-13-11-22(12-14-23)21-19(10-15-24-22)18-8-4-5-9-20(18)25-21/h1-9H,10-16H2 BXTAXLWLFOLFKL-UHFFFAOYSA-N
OSM-S-214 GSK3376900A CC1=CC(CN(CC2)CCC32C4=C(SC=C4)CCO3)=C(C)N1C5=CC=C(F)C=C5 InChI=1S/C24H27FN2OS/c1-17-15-19(18(2)27(17)21-5-3-20(25)4-6-21)16-26-11-9-24(10-12-26)22-8-14-29-23(22)7-13-28-24/h3-6,8,14-15H,7,9-13,16H2,1-2H3 JOUHIYBEDRSIMN-UHFFFAOYSA-N
OSM-S-216 GSK3376901A O=C(C1=CC=CC=C1)N(CC2)CCC32C4=C(SC=C4)CCO3 InChI=1S/C18H19NO2S/c20-17(14-4-2-1-3-5-14)19-10-8-18(9-11-19)15-7-13-22-16(15)6-12-21-18/h1-5,7,13H,6,8-12H2 DJCDYAUIXOORLS-UHFFFAOYSA-N
Location of files for this page: